(Recorded live on Tuesday, July 14, 2020) Biomarkers are important tools for successful biopharmaceutical-targeted drug development and regulatory approval. Biomarkers can be diagnostic and/or prognostic, indicative of precision drug targeting. As such, biomarkers are...
(Recorded live on Thursday, April 16, 2020) Image analysis of histological tissue sections is a fast-growing field that is becoming widely accepted as a research tool for scientists and pathologists, providing quantitative, reproducible data in lieu of varying manual...
Flagship was a virtual exhibitor this year during the AACR Virtual Meeting II. Our scientists, led by Chuck Caldwell, shared a new poster during the virtual event.
EXHIBITING – BOOTH #802 AT MOLECULAR MED TRI-CON 2020March 1-4, 2020 Moscone Center, San Francisco, CA Visit our booth to learn about Flagship’s services that bring efficiencies and accuracy to clinical development by changing the paradigm of traditional pathology,...
Recruiting/Exhibiting – 5th Annual Life Science Industry ShowcaseFebruary 19, 2020 Aurora, CO Visit Flagship at our table at this networking event, which connects Colorado biotech, pharmaceutical, medical device, and diagnostic companies with students from Colorado...
EXHIBITING – THE 5TH ANNUAL MARKETSANDMARKETS BIOMARKER AND COMPANION DIAGNOSTICS CONFERENCEFebruary 6-7, 2020 San Diego, CA Visit us at the show in San Diego to meet several of Flagship’s leaders in science and business and to discuss your biomarker and tissue data...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
OverviewDuring a recent panel discussion, members of the Flagship Biosciences team and representatives from The Johns Hopkins University, Leap Therapeutics, and Corritori Consulting shared their thoughts on companion diagnostics development, with an emphasis on...
Introduction and BackgroundDr. Roberto Gianani, Chief Medical Officer at Flagship Biosciences, Inc., is a practicing pathologist who is board certified in anatomic pathology, clinical pathology, and pediatric pathology. He is fellowship-trained in surgical pathology...
Introduction and BackgroundAdam Beharry, PhD, is a Flagship scientist who describes his work as applying advanced technical knowledge and critical thinking to expand Flagship’s tissue image analysis in neuromuscular and rare diseases. Adam’s degrees include: BS –...
PUBLICATIONS/POSTERS
ABSTRACT In vitro diagnostic (IVD) approvals of qualitative immunohistochemical (IHC) assays offer unique patient selection strategies by equipping pathologists with new tools to assess tumor status including tumor immune landscape. PD-L1/PD-1 checkpoint therapies...
Key Takeaways Successful pathology AI does not replace, but assist pathologists in high-complexity tissue analysis Transparency and control is retained in a pathologist-centric AI-based system Pathology AI enables cost effective healthcare by testing for multiple...
Key takeaways Building Predictive Models of Clinical Outcomes in Immune Oncology Using Computational Tissue Analysis Scorecards The spatial location of PD-L1 expression can identify patients who will likely respond to anti-PD-1/PD-L1 therapy Flagship’s unique spatial...